JP2011500658A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500658A5
JP2011500658A5 JP2010529461A JP2010529461A JP2011500658A5 JP 2011500658 A5 JP2011500658 A5 JP 2011500658A5 JP 2010529461 A JP2010529461 A JP 2010529461A JP 2010529461 A JP2010529461 A JP 2010529461A JP 2011500658 A5 JP2011500658 A5 JP 2011500658A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
motomeko
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010529461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500658A (ja
Filing date
Publication date
Priority claimed from GBGB0720389.6A external-priority patent/GB0720389D0/en
Application filed filed Critical
Publication of JP2011500658A publication Critical patent/JP2011500658A/ja
Publication of JP2011500658A5 publication Critical patent/JP2011500658A5/ja
Pending legal-status Critical Current

Links

JP2010529461A 2007-10-18 2008-10-20 アゼチジニルｇタンパク質共役受容体アゴニスト Pending JP2011500658A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0720389.6A GB0720389D0 (en) 2007-10-18 2007-10-18 G-Protein Coupled Receptor Agonists
PCT/GB2008/050970 WO2009050522A1 (en) 2007-10-18 2008-10-20 Azetidinyl g-protein coupled receptor agonists

Publications (2)

Publication Number Publication Date
JP2011500658A JP2011500658A (ja) 2011-01-06
JP2011500658A5 true JP2011500658A5 (https=) 2011-12-08

Family

ID=40042244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010529461A Pending JP2011500658A (ja) 2007-10-18 2008-10-20 アゼチジニルｇタンパク質共役受容体アゴニスト

Country Status (5)

Country Link
US (1) US20110059942A1 (https=)
EP (1) EP2215077A1 (https=)
JP (1) JP2011500658A (https=)
GB (1) GB0720389D0 (https=)
WO (1) WO2009050522A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399914A4 (en) * 2009-02-18 2012-08-29 Takeda Pharmaceutical FUSED HETEROCYCLIC CORE COMPOUND
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
WO2011044001A1 (en) * 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012066077A1 (en) 2010-11-18 2012-05-24 Prosidion Limited 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CA3026903C (en) 2016-06-09 2024-05-28 Pramana Pharmaceuticals Inc. Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119
US11358956B2 (en) 2017-11-30 2022-06-14 Pramana Pharmaceuticals Inc. Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
EP1123391A2 (en) 1998-09-01 2001-08-16 BASF Aktiengesellschaft Methods for improving the function of heterologous g protein-coupled receptors
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
CA2457922A1 (en) 2001-08-31 2003-03-13 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
IL157704A0 (en) 2001-09-21 2004-03-28 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
KR100903760B1 (ko) 2001-09-21 2009-06-19 솔베이 파마슈티칼스 비. 브이 Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2833842B1 (fr) 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
EP1482794A1 (en) 2002-03-06 2004-12-08 Merck & Co., Inc. Method of treatment or prevention of obesity
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
AR041786A1 (es) * 2002-03-15 2005-06-01 Novartis Ag Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
AU2003215024B2 (en) 2002-03-26 2008-02-21 Merck Sharp & Dohme Corp. Spirocyclic amides as cannabinoid receptor modulators
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
US20050154202A1 (en) 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
JP4202319B2 (ja) 2002-07-29 2008-12-24 エフ．ホフマン−ラ ロシュ アーゲー 新規ベンゾジオキソール
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
WO2004034968A2 (en) 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
HRP20050053A2 (en) 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
US20040077650A1 (en) 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
GB0230087D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
KR100674769B1 (ko) 2003-01-02 2007-02-28 에프. 호프만-라 로슈 아게 신규 씨비 1 수용체 역작용제
CN101012193A (zh) 2003-01-02 2007-08-08 霍夫曼-拉罗奇有限公司 新cb 1受体反激动剂
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2004072077A1 (de) 2003-02-13 2004-08-26 Aventis Pharma Deutshland Gmbh STICKSTOFF SUBSTITUIERTE HEXAHYDRO-PYRAZINO[1,2-a]PYRIMIDIN-4,7-DIONDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL
RU2005128497A (ru) 2003-02-13 2006-01-27 Санофи-Авентис Дойчленд Гмбх (De) Замещенные производные гексагидропиразино (1,2-а) пиримидин-4,7-диона, способы их получения и их применение в качестве лекарственных средств
EP1606019A1 (en) 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
JP4958560B2 (ja) 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
NZ556017A (en) 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
JP2008545010A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
NZ571869A (en) 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists

Similar Documents

Publication Publication Date Title
JP2011500658A5 (https=)
JP2010514832A5 (https=)
JP2010514831A5 (https=)
JP2011527332A5 (https=)
JP2011527335A5 (https=)
JP2011500659A5 (https=)
JP2011527333A5 (https=)
JP2011527331A5 (https=)
JP2011527334A5 (https=)
JP2009533410A5 (https=)
JP2006143751A5 (https=)
JP2008525416A5 (https=)
JP2009532453A5 (https=)
CY1111310T1 (el) Ενωσεις για την αγωγη μεταβολικων διαταραχων
JP2008526724A5 (https=)
JP2013512277A5 (https=)
JP2012512863A5 (https=)
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
JP2010077141A5 (https=)
EP2266946A3 (en) Compound For The Treatment Of Metabolic Disorders
JP2012513416A5 (https=)
JP2005511547A5 (https=)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
UA95613C2 (ru) Соединения для лечения расстройсв метаболизма
MXPA05011592A (es) Compuestos para el tratamiento de trastornos metabolicos.